Stay updated on Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page revision/version label was updated from v3.5.2 to v3.5.3, reflecting a site or interface version change rather than any update to the clinical trial record itself.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision v3.5.0 was added to the record history and Revision v3.4.3 was removed.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision history updated: added v3.4.3 and removed v3.4.2.SummaryDifference0.1%

- Check91 days agoChange DetectedAdded Revision: v3.4.2 to the history; deletions remove a government-funding notice and the older Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check98 days agoChange DetectedAdded a government funding lapse notice and a revision note (v3.4.1); removed the previous revision note (v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.